Evidence map›Paper›PMID 41521321›Full record

ReviewJournal of hematology & oncology2026

Molecularly targeted therapy and immunotherapy in leukemias.

Elie Cousin, Agathe Picard, Maria Oundjian, Nina Tardif, Anaïs Quemener, Anne-Gaëlle Rio, Marie-Dominique Galibert, Virginie Gandemer, Frédéric Mazurier

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elie CousinIGDR (Institut de Génétique Et Développement de Rennes)UMR 6290, ERL U13052 Av du Professeur Léon Bernard, Univ Rennes, CNRS, INSERM, Equipe Labellisée Ligue Nationale Contre Le Cancer, Bâtiment 4, 35000, Rennes, France. elie.cousin@univ-rennes.fr.
Agathe PicardDepartment of Pediatric Hematology and Oncology, University Hospital of Rennes (CHU Rennes), 35000, Rennes, France.
Maria OundjianIGDR (Institut de Génétique Et Développement de Rennes)UMR 6290, ERL U13052 Av du Professeur Léon Bernard, Univ Rennes, CNRS, INSERM, Equipe Labellisée Ligue Nationale Contre Le Cancer, Bâtiment 4, 35000, Rennes, France.
Nina TardifIGDR (Institut de Génétique Et Développement de Rennes)UMR 6290, ERL U13052 Av du Professeur Léon Bernard, Univ Rennes, CNRS, INSERM, Equipe Labellisée Ligue Nationale Contre Le Cancer, Bâtiment 4, 35000, Rennes, France.
Anaïs QuemenerIGDR (Institut de Génétique Et Développement de Rennes)UMR 6290, ERL U13052 Av du Professeur Léon Bernard, Univ Rennes, CNRS, INSERM, Equipe Labellisée Ligue Nationale Contre Le Cancer, Bâtiment 4, 35000, Rennes, France.
Anne-Gaëlle RioIGDR (Institut de Génétique Et Développement de Rennes)UMR 6290, ERL U13052 Av du Professeur Léon Bernard, Univ Rennes, CNRS, INSERM, Equipe Labellisée Ligue Nationale Contre Le Cancer, Bâtiment 4, 35000, Rennes, France.
Marie-Dominique GalibertIGDR (Institut de Génétique Et Développement de Rennes)UMR 6290, ERL U13052 Av du Professeur Léon Bernard, Univ Rennes, CNRS, INSERM, Equipe Labellisée Ligue Nationale Contre Le Cancer, Bâtiment 4, 35000, Rennes, France.
Virginie GandemerIGDR (Institut de Génétique Et Développement de Rennes)UMR 6290, ERL U13052 Av du Professeur Léon Bernard, Univ Rennes, CNRS, INSERM, Equipe Labellisée Ligue Nationale Contre Le Cancer, Bâtiment 4, 35000, Rennes, France.
Frédéric MazurierIGDR (Institut de Génétique Et Développement de Rennes)UMR 6290, ERL U13052 Av du Professeur Léon Bernard, Univ Rennes, CNRS, INSERM, Equipe Labellisée Ligue Nationale Contre Le Cancer, Bâtiment 4, 35000, Rennes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of next-generation high-throughput sequencing and precision medicine has allowed the identification of recurrent genetic events of vital interest for leukemic cells and for the management of patients with leukemia, since it has a direct impact on prognosis and therapeutic stratification. The precise cytogenetic characterization of these diseases has rapidly enabled the development of innovative therapeutic strategies to improve outcomes and limit toxicities. New targeted therapies, including small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug conjugates, recombinant immunotoxins, and chimeric antigen receptor T cells (CAR-T cells) represent a broad therapeutic arsenal now available in everyday practice. The growing number of treatments means that many possibilities of drugs and combinations can be used to offer new lines of therapy in cases of refractory disease or relapse, but also in frontline treatment. This review provides a broad overview of pathogenic mechanisms and therapies (including targeted therapies, immunotherapy and RNA-based therapy) and gathers the main research progress in the field of leukemia.

Indexed as

ImmunotherapyLeukemiaMolecular Targeted TherapyAnimalsAntibodies, MonoclonalHumansAntibodies, MonoclonalAntisense oligonucleotidesImmunotherapyLeukemiaTargeted therapy

Identifiers

PMID41521321
PMCPMC12810010

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.